Takayasu Arteritis
50
14
15
19
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.0%
2 terminated out of 50 trials
90.5%
+3.9% vs benchmark
22%
11 trials in Phase 3/4
11%
2 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (50)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Cardiovascular Risk in Patients With Takayasu Arteritis: A Nationwide Population-Based Cohort Study
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Upadacitinib for Refractory Takayasu Arteritis
Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
VCRC Tissue Repository
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
Effect of Pirfenidone on TA Fibrosis
Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Controls
Surgery Benefits Takayasu Arteritis With Stenosis in the Descending Aorta
Turkish Adaptation of the VascuQoL-6 Quality of Life Scale
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
Takayasu Arteritis Clinical Trial in China
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Baricitinib for Refractory Takayasu Arteritis